newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

  • Bezuclastinib combination demonstrated statistically significant improvement in progression-free survival (PFS) versus sunitinib monotherapy in GIST patients, with median PFS of 16.5 months versus 9.2 months (HR=0.50, p<0.0001).
  • The combination showed clear PFS benefits across all primary & secondary KIT mutation subgroups.
  • Mean duration of treatment for the bezuclastinib combination is estimated at 21.4 months.
  • The combination achieved an objective response rate (ORR) of 46% in imatinib-resistant patients compared to 26% for sunitinib alone.
  • Safety profile was generally well-tolerated with no unique risks observed compared to sunitinib monotherapy.
  • Priority Review status was granted by the FDA for the New Drug Application (NDA), with a PDUFA date set for November 30, 2026.
  • Median PFS2 (time to next therapy or death) was not reached for the combination arm versus 21 months for sunitinib.
  • Cogent Biosciences initiated a new single-arm clinical trial evaluating the combination in first-line GIST patients with KIT exon 9 mutations.
  • Expanded Access Programs (EAPs) are active for U.S. patients with GIST or systemic mastocytosis who meet specific criteria.